tetano
Editor, Senior Moderator
Pathogens
. 2021 Nov 18;10(11):1505.
doi: 10.3390/pathogens10111505.
Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
Cheng Xiao[SUP] 1 [/SUP], Nancy Hiu Lan Leung[SUP] 2 [/SUP], Yating Cheng[SUP] 3 4 [/SUP], Hui Lei[SUP] 1 [/SUP], Shiman Ling[SUP] 1 [/SUP], Xia Lin[SUP] 1 [/SUP], Ran Tao[SUP] 3 4 [/SUP], Xianzhong Huang[SUP] 3 4 [/SUP], Wenda Guan[SUP] 1 [/SUP], Zifeng Yang[SUP] 1 5 [/SUP], Benjamin John Cowling[SUP] 2 [/SUP], Mark Zanin[SUP] 1 2 [/SUP], Sook-San Wong[SUP] 1 2 [/SUP]
Affiliations
Abstract
Guangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies against SARS-CoV-2 after the emergence of COVID-19 in Guangdong. We tested 14,629 residual serum samples that were submitted for clinical testing from 21 prefectures between March and June 2020 for SARS-CoV-2 antibodies using a magnetic particle based chemiluminescent enzyme immunoassay and validated the results using a pseudovirus neutralization assay. We found 21 samples positive for SARS-CoV-2 IgG, resulting in an estimated age- and sex-weighted seroprevalence of 0.15% (95% CI: 0.06-0.24%). The overall age-specific seroprevalence was 0.07% (95% CI: 0.01-0.24%) in persons up to 9 years old, 0.22% (95% CI: 0.03-0.79%) in persons aged 10-19, 0.16% (95% CI: 0.07-0.33%) in persons aged 20-39, 0.13% (95% CI: 0.03-0.33%) in persons aged 40-59 and 0.18% (95% CI: 0.07-0.40%) in persons ≥60 years old. Fourteen (67%) samples had pseudovirus neutralization titers to S-protein, suggesting most of the IgG-positive samples were true-positives. Seroprevalence of antibodies to SARS-CoV-2 was low, indicating that there were no hidden epidemics during this period. Vaccination is urgently needed to increase population immunity to SARS-CoV-2.
Keywords: China; Guangdong; SARS-CoV-2; antibody; coronavirus disease 2019; seroprevalence.
. 2021 Nov 18;10(11):1505.
doi: 10.3390/pathogens10111505.
Seroprevalence of Antibodies to SARS-CoV-2 in Guangdong Province, China between March to June 2020
Cheng Xiao[SUP] 1 [/SUP], Nancy Hiu Lan Leung[SUP] 2 [/SUP], Yating Cheng[SUP] 3 4 [/SUP], Hui Lei[SUP] 1 [/SUP], Shiman Ling[SUP] 1 [/SUP], Xia Lin[SUP] 1 [/SUP], Ran Tao[SUP] 3 4 [/SUP], Xianzhong Huang[SUP] 3 4 [/SUP], Wenda Guan[SUP] 1 [/SUP], Zifeng Yang[SUP] 1 5 [/SUP], Benjamin John Cowling[SUP] 2 [/SUP], Mark Zanin[SUP] 1 2 [/SUP], Sook-San Wong[SUP] 1 2 [/SUP]
Affiliations
- PMID: 34832661
- DOI: 10.3390/pathogens10111505
Abstract
Guangdong province, located in South China, is an important economic hub with a large domestic migrant population and was among the earliest areas to report COVID-19 cases outside of Wuhan. We conducted a cross-sectional, age-stratified serosurvey to determine the seroprevalence of antibodies against SARS-CoV-2 after the emergence of COVID-19 in Guangdong. We tested 14,629 residual serum samples that were submitted for clinical testing from 21 prefectures between March and June 2020 for SARS-CoV-2 antibodies using a magnetic particle based chemiluminescent enzyme immunoassay and validated the results using a pseudovirus neutralization assay. We found 21 samples positive for SARS-CoV-2 IgG, resulting in an estimated age- and sex-weighted seroprevalence of 0.15% (95% CI: 0.06-0.24%). The overall age-specific seroprevalence was 0.07% (95% CI: 0.01-0.24%) in persons up to 9 years old, 0.22% (95% CI: 0.03-0.79%) in persons aged 10-19, 0.16% (95% CI: 0.07-0.33%) in persons aged 20-39, 0.13% (95% CI: 0.03-0.33%) in persons aged 40-59 and 0.18% (95% CI: 0.07-0.40%) in persons ≥60 years old. Fourteen (67%) samples had pseudovirus neutralization titers to S-protein, suggesting most of the IgG-positive samples were true-positives. Seroprevalence of antibodies to SARS-CoV-2 was low, indicating that there were no hidden epidemics during this period. Vaccination is urgently needed to increase population immunity to SARS-CoV-2.
Keywords: China; Guangdong; SARS-CoV-2; antibody; coronavirus disease 2019; seroprevalence.